Competing central nervous system or systemic progression analysis for patients with EGFR mutation-positive NSCLC receiving afatinib in LUX-Lung 3, 6, and 7

被引：5

作者：

Yang, J. C-H. ^{[1
,2
]}

Wu, Y-L. ^{[3
,4
]}

Hirsh, V. ^{[5
]}

O'Byrne, K. ^{[6
]}

Yamamoto, N. ^{[7
]}

Popat, S. ^{[8
]}

Tamiya, A. ^{[9
]}

Maerten, A. ^{[10
]}

Schuler, M. ^{[11
]}

机构：

[1] Natl Taiwan Univ Hosp, Taipei, Taiwan

[2] Natl Taiwan Univ, Ctr Canc, Taipei, Taiwan

[3] Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China

[4] Guangdong Acad Med Sci, Guangzhou, Guangdong, Peoples R China

[5] McGill Univ, Montreal, PQ, Canada

[6] Princess Alexandra Hosp, Brisbane, Qld, Australia

[7] Wakayama Med Univ Hosp, Wakayama, Japan

[8] Royal Marsden Hosp, London, England

[9] Kinki Chuo Chest Med Ctr, Osaka, Japan

[10] Boehringer Ingelheim Int GmbH, Ingelheim, Germany

[11] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany

来源：

关键词：

D O I：

10.1016/S1556-0864(18)30417-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

143PD

引用

页码：S84 / S85

页数：2